Can a radioactive tracer reveal hidden lung scarring?

NCT ID NCT05365802

Ongoing Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether a radioactive tracer called 68Ga-FAPi-46 can light up areas of scarring (fibrosis) in the lungs of people with interstitial lung disease. Participants receive the tracer and undergo a PET/CT scan to see where it collects. The goal is to understand how the tracer behaves in normal and diseased lung tissue, which may improve how doctors image and monitor this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPi-46, a radioactive tracer given by injection for PET imaging
What this could lead to: If successful, this could lead to better imaging methods to see and measure lung fibrosis, helping guide treatment decisions for interstitial lung disease.
What could go wrong: This is an early, exploratory study with only 30 participants, so results may not apply broadly. The tracer's accuracy in reflecting disease activity is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-INDUCED PNEUMONITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis idiopathic interstitial pneumonia interstitial lung disease pneumoconiosis pulmonary fibrosis radiation pneumonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-INDUCED PNEUMONITIS HYPERSENSITIVITY PNEUMONITIS IDIOPATHIC INTERSTITIAL PNEUMONIAS INTERSTITIAL LUNG DISEASE PNEUMOCONIOSIS PULMONARY FIBROSIS RADIATION PNEUMONITIS

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.